Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy

Shashi Prasad, Virginia Cody, Jennifer K. Saucier-Sawyer, W. Mark Saltzman, Clarence T. Sasaki, Richard L. Edelson, Martin A. Birchall, Douglas J. Hanlon

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Encapsulation of tumor-associated antigens in polymer nanoparticles (NP) is a promising approach to enhance efficiency of antigen delivery for anti-tumor vaccines. Head and neck squamous carcinoma (HNSCC) cell lines were initially used to generate tumor-associated antigens (TAA)-containing poly (lactic-co-glycolic acid) (PLGA) NP; encapsulation efficiency and release kinetics were profiled. Findings were adopted to entrap fresh tumor lysate from five patients with advanced HNSCC. To test the hypothesis that NP enhance antigen presentation, dendritic cell (DC) produced from patient blood monocyte precursors were loaded with either the un-encapsulated or NP-encapsulated versions of tumor lysates. These were used to stimulate freshly-isolated autologous CD8+ T cells. In four of five patients, anti-tumor CD8+ T cells showed significantly increased immunostimulatory IFN-γ (p=0.071) or decreased immmunoinhibitory IL-10 production (p=0.0004) associated with NP-mediated antigen delivery. The observations represent an enabling step in the production of clinically-translatable, inexpensive, highly-efficient, and personalized polymer-based immunotherapy for solid organ malignancies. From the Clinical Editor: Enhancing the antigen presentation may be a viable approach to increase the efficiency of tumor cell directed cytotoxicity via immune mechanisms. This study presents an example for this using head and neck cancer cell lines and nanotechnology-based encapsulated antigen presentation to dendritic cells. The observed CD8+ T-cell response was significantly enhanced. This method may pave the way to a highly efficient cancer cell elimination method with minimal to no toxicity.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume7
Issue number1
DOIs
StatePublished - Feb 2011
Externally publishedYes

Fingerprint

Antigens
Immunotherapy
Nanoparticles
Dendritic Cells
Tumors
Polymers
Antigen Presentation
T-cells
Neoplasms
Neoplasm Antigens
T-Lymphocytes
Cells
Squamous Cell Carcinoma
Encapsulation
Neck
Head
Cell Line
Cancer Vaccines
Nanotechnology
Head and Neck Neoplasms

Keywords

  • Antigen delivery
  • Dendritic cell
  • Immunotherapy
  • Nanoparticles
  • Polymers

ASJC Scopus subject areas

  • Molecular Medicine
  • Bioengineering
  • Biomedical Engineering
  • Materials Science(all)
  • Medicine (miscellaneous)
  • Pharmaceutical Science

Cite this

Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy. / Prasad, Shashi; Cody, Virginia; Saucier-Sawyer, Jennifer K.; Saltzman, W. Mark; Sasaki, Clarence T.; Edelson, Richard L.; Birchall, Martin A.; Hanlon, Douglas J.

In: Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 7, No. 1, 02.2011, p. 1-10.

Research output: Contribution to journalArticle

Prasad, Shashi ; Cody, Virginia ; Saucier-Sawyer, Jennifer K. ; Saltzman, W. Mark ; Sasaki, Clarence T. ; Edelson, Richard L. ; Birchall, Martin A. ; Hanlon, Douglas J. / Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy. In: Nanomedicine: Nanotechnology, Biology, and Medicine. 2011 ; Vol. 7, No. 1. pp. 1-10.
@article{61bf04b2c74d4c5782c533990f230c79,
title = "Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy",
abstract = "Encapsulation of tumor-associated antigens in polymer nanoparticles (NP) is a promising approach to enhance efficiency of antigen delivery for anti-tumor vaccines. Head and neck squamous carcinoma (HNSCC) cell lines were initially used to generate tumor-associated antigens (TAA)-containing poly (lactic-co-glycolic acid) (PLGA) NP; encapsulation efficiency and release kinetics were profiled. Findings were adopted to entrap fresh tumor lysate from five patients with advanced HNSCC. To test the hypothesis that NP enhance antigen presentation, dendritic cell (DC) produced from patient blood monocyte precursors were loaded with either the un-encapsulated or NP-encapsulated versions of tumor lysates. These were used to stimulate freshly-isolated autologous CD8+ T cells. In four of five patients, anti-tumor CD8+ T cells showed significantly increased immunostimulatory IFN-γ (p=0.071) or decreased immmunoinhibitory IL-10 production (p=0.0004) associated with NP-mediated antigen delivery. The observations represent an enabling step in the production of clinically-translatable, inexpensive, highly-efficient, and personalized polymer-based immunotherapy for solid organ malignancies. From the Clinical Editor: Enhancing the antigen presentation may be a viable approach to increase the efficiency of tumor cell directed cytotoxicity via immune mechanisms. This study presents an example for this using head and neck cancer cell lines and nanotechnology-based encapsulated antigen presentation to dendritic cells. The observed CD8+ T-cell response was significantly enhanced. This method may pave the way to a highly efficient cancer cell elimination method with minimal to no toxicity.",
keywords = "Antigen delivery, Dendritic cell, Immunotherapy, Nanoparticles, Polymers",
author = "Shashi Prasad and Virginia Cody and Saucier-Sawyer, {Jennifer K.} and Saltzman, {W. Mark} and Sasaki, {Clarence T.} and Edelson, {Richard L.} and Birchall, {Martin A.} and Hanlon, {Douglas J.}",
year = "2011",
month = "2",
doi = "10.1016/j.nano.2010.07.002",
language = "English (US)",
volume = "7",
pages = "1--10",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy

AU - Prasad, Shashi

AU - Cody, Virginia

AU - Saucier-Sawyer, Jennifer K.

AU - Saltzman, W. Mark

AU - Sasaki, Clarence T.

AU - Edelson, Richard L.

AU - Birchall, Martin A.

AU - Hanlon, Douglas J.

PY - 2011/2

Y1 - 2011/2

N2 - Encapsulation of tumor-associated antigens in polymer nanoparticles (NP) is a promising approach to enhance efficiency of antigen delivery for anti-tumor vaccines. Head and neck squamous carcinoma (HNSCC) cell lines were initially used to generate tumor-associated antigens (TAA)-containing poly (lactic-co-glycolic acid) (PLGA) NP; encapsulation efficiency and release kinetics were profiled. Findings were adopted to entrap fresh tumor lysate from five patients with advanced HNSCC. To test the hypothesis that NP enhance antigen presentation, dendritic cell (DC) produced from patient blood monocyte precursors were loaded with either the un-encapsulated or NP-encapsulated versions of tumor lysates. These were used to stimulate freshly-isolated autologous CD8+ T cells. In four of five patients, anti-tumor CD8+ T cells showed significantly increased immunostimulatory IFN-γ (p=0.071) or decreased immmunoinhibitory IL-10 production (p=0.0004) associated with NP-mediated antigen delivery. The observations represent an enabling step in the production of clinically-translatable, inexpensive, highly-efficient, and personalized polymer-based immunotherapy for solid organ malignancies. From the Clinical Editor: Enhancing the antigen presentation may be a viable approach to increase the efficiency of tumor cell directed cytotoxicity via immune mechanisms. This study presents an example for this using head and neck cancer cell lines and nanotechnology-based encapsulated antigen presentation to dendritic cells. The observed CD8+ T-cell response was significantly enhanced. This method may pave the way to a highly efficient cancer cell elimination method with minimal to no toxicity.

AB - Encapsulation of tumor-associated antigens in polymer nanoparticles (NP) is a promising approach to enhance efficiency of antigen delivery for anti-tumor vaccines. Head and neck squamous carcinoma (HNSCC) cell lines were initially used to generate tumor-associated antigens (TAA)-containing poly (lactic-co-glycolic acid) (PLGA) NP; encapsulation efficiency and release kinetics were profiled. Findings were adopted to entrap fresh tumor lysate from five patients with advanced HNSCC. To test the hypothesis that NP enhance antigen presentation, dendritic cell (DC) produced from patient blood monocyte precursors were loaded with either the un-encapsulated or NP-encapsulated versions of tumor lysates. These were used to stimulate freshly-isolated autologous CD8+ T cells. In four of five patients, anti-tumor CD8+ T cells showed significantly increased immunostimulatory IFN-γ (p=0.071) or decreased immmunoinhibitory IL-10 production (p=0.0004) associated with NP-mediated antigen delivery. The observations represent an enabling step in the production of clinically-translatable, inexpensive, highly-efficient, and personalized polymer-based immunotherapy for solid organ malignancies. From the Clinical Editor: Enhancing the antigen presentation may be a viable approach to increase the efficiency of tumor cell directed cytotoxicity via immune mechanisms. This study presents an example for this using head and neck cancer cell lines and nanotechnology-based encapsulated antigen presentation to dendritic cells. The observed CD8+ T-cell response was significantly enhanced. This method may pave the way to a highly efficient cancer cell elimination method with minimal to no toxicity.

KW - Antigen delivery

KW - Dendritic cell

KW - Immunotherapy

KW - Nanoparticles

KW - Polymers

UR - http://www.scopus.com/inward/record.url?scp=78751681345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751681345&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2010.07.002

DO - 10.1016/j.nano.2010.07.002

M3 - Article

VL - 7

SP - 1

EP - 10

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

IS - 1

ER -